Evotec stock steadies after H1 2026 earnings and guidance cut

Evotec SE (ISIN DE0005664809) stock is trading around €3.72 on Nasdaq as of August 12, 2026, with a 4.29% gain at the close following the release of its second quarter and first half 2026 results and updated guidance reported on August 13, 2026.

Q2 2026 shows revenue drop and EBITDA loss

According to Evotecs second quarter and half-year 2026 report published on August 13, 2026, group revenues in Q2 2026 came in at €143.5 million, down from €171.2 million in Q2 2025, a decline of 16.2% year over year.

The company also reported adjusted group EBITDA of -€20.8 million for Q2 2026, compared with a positive level in the prior year, highlighting how cost pressures and portfolio shifts have pushed the business into a quarterly loss even as commercial momentum remains in selected segments.

Half-year 2026 performance and full-year outlook reset

For the first half of 2026, Evotec generated group revenues of €300.1 million, compared with €313.2 million on a constant-currency basis, indicating a modest 4.2% decrease versus the prior-year half while still reflecting a sizable revenue base across its discovery and development partnerships.

On profitability, adjusted group EBITDA for H1 2026 was -€42.7 million, versus -€37.4 million on a constant-currency basis, showing that the loss widened by around €5.3 million despite ongoing efforts to optimize the cost base and footprint.

Alongside the results, Evotec confirmed a significantly lowered full-year 2026 outlook, now guiding for group revenues of approximately €570 million to €610 million compared with a previously stated range of €700 million to €780 million, implying a cut of up to €210 million at the top end of the range.

The company also now expects adjusted group EBITDA for 2026 to be between -€70 million and -€105 million, a substantial downgrade from the earlier guidance of €0 million to €40 million, underscoring the depth of profit headwinds that had already been flagged in the July profit warning and are now quantified for the remainder of the year.

Market reaction and US listing context

Evotecs American Depositary Shares trade on Nasdaq under the symbol EVO, giving US investors exposure to the German drug discovery group in US dollars even though its primary operations and many of its trading references remain anchored in euros.

Market data compiled by MarketBeat for the Q2 2026 earnings context show the Nasdaq-listed Evotec ADS closing at $2.19 on August 12, 2026, up $0.09 or 4.29% from the previous session, before easing to $2.06 in extended trading, reflecting some initial relief but ongoing caution around the reduced guidance.

In parallel, quotes from European trading venues cited by recent coverage indicate the Frankfurt-listed Evotec shares changing hands at around €3.716, up roughly 1.2% on August 12, 2026, and still more than 50% below a November peak of €7.75, positioning the current price as a rebound from recent lows rather than a full recovery.

Representative product and research platform

Beyond the short-term earnings volatility, Evotecs core business centers on integrated drug discovery and development platforms that support pharmaceutical and biotech partners across multiple therapeutic areas, with particular emphasis on early-stage discovery, hit identification, and project progression.

Through its combining of high-throughput screening technologies, medicinal chemistry capabilities, and data-driven translational biology, Evotec aims to generate candidate molecules and partnered assets that can advance into clinical development, providing a pipeline of potential milestones and royalties that sit alongside its more transactional service revenues.

Evotec stock level in the current session

As of August 12, 2026, 4:00 p.m. ET, Evotecs ADS on Nasdaq closed at $2.19, while recent Frankfurt pricing around €3.72 shows the shares trading well below prior highs but modestly above the early-July trough, indicating that the post-warning adjustment and fresh guidance have been partly absorbed by the market even as investors continue to weigh the path back to profitability.